BioXcel Therapeutics, Inc.
BTAINASDAQHealthcareDrug Manufacturers - Specialty & Generic
As of Oct 8, 2026 close
- Market cap
- $1.45M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.02$2.76
- Volume (live)
- -
- Avg. volume (3M)
- 11.74M
BioXcel Therapeutics (BTAI) Stock Price & Financial Analysis
BioXcel Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $0.04 - $0.06 |
|---|---|
| 52-Week High | $2.76 |
| 52-Week Low | $0.02 |
| Open | $0.05 |
| Volume (last close) | 70.58K |
| Average Volume (3M) | 11.74M |
| Revenue (TTM) | 742.00K |
|---|---|
| Net Income (TTM) | -70.86M |
| Free Cash Flow (TTM) | -50.90M |
| EPS (TTM) | −$3.53 |
| Profit Margin | -9549.87% |
| Operating Margin | -6028.57% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 1.45M |
|---|---|
| Shares Outstanding | 30.30M |
| Price to Sales (P/S) | 1.96 |
| Price to Book (P/B) | -0.01 |
| EV/EBITDA | -1.69 |
| 50-Day MA | $0.40 |
|---|---|
| 200-Day MA | $1.12 |
| 1-Year Change | −97.93% |
Source: Market prices and company fundamentals. Data as of Oct 8, 2026. Data sources and methodology
BioXcel Therapeutics at a Glance
As of the Oct 8, 2026 close, BioXcel Therapeutics (BTAI) has a market capitalization of $1.45M. The stock trades at 2.0× sales. Over the trailing twelve months it lost $70.86M on revenue of $742.00K and burned $50.90M of free cash flow. Revenue fell 14.5% year over year.
As of its latest reported balance sheet, it holds $12.84M in cash and securities against $104.45M of debt, a net debt position of $91.61M.
BioXcel Therapeutics does not currently pay a dividend.
The share price is down 97.9% over the past year. At $0.05 (the Oct 8, 2026 close) it sits near the bottom of its 52-week range of $0.02 to $2.75, below its 200-day moving average of $1.12.
Based on 1 professional analyst rating from the past 90 days, the consensus is Hold.
Frequently Asked Questions About BioXcel Therapeutics
What is the current stock price for BTAI?
As of the Oct 8, 2026 close, BTAI stock trades at $0.05. The 52-week range is $0.02–$2.76, with a day range of $0.04–$0.06.
What is the P/E ratio for BTAI?
The P/E ratio (Price-to-Earnings) for BTAI is shown in the Key Statistics section. This valuation metric helps compare BioXcel Therapeutics, Inc. to industry peers.
Does BTAI pay dividends?
BioXcel Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for BTAI?
Based on ratings from 1 professional analyst over the last 90 days, the consensus for BTAI is Hold.
What is the market cap of BTAI?
As of the Oct 8, 2026 close, BioXcel Therapeutics's market capitalization is $1.5M, classifying it as a micro-cap company. BioXcel Therapeutics operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.